"Mount Sinai Licenses Tech For New Allergy Test" - Jennifer Henderson
Mount Sinai Health System has licensed technology for allergy detection and management to AllerGenis , a diagnostics company based in Hatfield, PA. The technology is an epitope mapping platform that subdivides protein allergens into epitopes, or smaller peptides, and measures how an individual’s antibody levels react to them. It was developed by Hugh Sampson, MD, director emeritus of the Elliot and Roslyn Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai. The mapping technology can predict which individuals will be allergic to specific foods as well as the severity of the allergy, said Erik Lium, PhD, executive vice president of Mount Sinai Innovation Partners. Predicting severity can aid in determining whether a patient will grow out of an allergy, be treated with immunotherapy, or should carry a potentially lifesaving EpiPen. AllerGenis plans to build a database of patients' epitope reactivity to help health care providers better assess and manage patients with food allergies.
— Erik Lium, PhD, Executive Vice President, Mount Sinai Innovation Partners
— Hugh Sampson, MD, Professor, Pediatrics, Allergy and Immunology, Director Emeritus, Elliot and Roslyn Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai
Learn more >(Subscription required)